Magneclo

Magnesium Chloride Hexahydrate, the active ingredient in Magneclo, is an electrolyte/mineral supplement presented as a solution for injection for intramuscular and intravenous use. It treats hypomagnesemia and magnesium deficiency in hospital and critical‑care settings.

GNH USA supplies Magneclo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Magneclo is used to replace magnesium in patients with electrolyte disturbances.

- Hypomagnesemia: restores plasma magnesium levels and supports neuromuscular function. - Magnesium deficiency: corrects low magnesium concentrations and aids enzymatic processes. - Peri‑operative electrolyte replacement: provides rapid magnesium repletion during surgery or critical care.

Magneclo may be associated with a range of adverse reactions, most of which are related to the route of administration or rapid changes in serum magnesium.

Common Side Effects: - Injection site pain: mild discomfort at the injection site. - Flushing: transient warmth or redness of the skin. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Hypermagnesemia: elevated serum magnesium that can cause cardiac arrhythmia or respiratory depression. - Allergic reaction: rash, itching, or anaphylaxis. - Cardiac arrest: severe conduction disturbances in extreme cases.

When using Magneclo, clinicians should observe several safety measures.

- Assess serum magnesium: measure baseline levels before initiating therapy. - Monitor cardiac function: observe ECG for QT changes during infusion. - Adjust dose in renal impairment: reduce or avoid in patients with severe renal failure. - Avoid rapid infusion: administer over recommended time to prevent hypermagnesemia. - Pregnancy and lactation: use only if benefit outweighs risk, as data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Magneclo can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Calcium‑containing solutions: concurrent infusion may precipitate magnesium‑calcium salts. - Neuromuscular blockers: enhanced potentiation leading to prolonged muscle relaxation. - Loop diuretics: may increase magnesium loss, requiring careful monitoring.

Moderate Interactions (Monitor Closely): - ACE inhibitors: risk of additive hypotensive effect. - Aminoglycoside antibiotics: potential for increased neuromuscular blockade. - Proton pump inhibitors: may affect magnesium absorption, monitor levels.